IPO WATCH- The Egyptian Financial Supervisory Authority (EFSA) signed off yesterday on DBK Pharma’s fair value assessment of EGP 3.1 per share ahead of the company's planned initial public offering of 35% of its shares, sources close to the matter tell Al Borsa. The report was prepared by financial consultancy firm FinCorp. We had last noted in May that DBK Pharma’s second attempt to list on the EGX had been running into roadblocks. DBK’s first attempt to IPO in 2015 had also failed when the company was unable to raise enough to cover its offering.

Tags: